Completed PHASE3 INTERVENTIONAL NCT00275665

The Study is Being Done to See if Taking the Drug Valganciclovir Can Prevent CMV Infection.

A Phase III Multicenter Study of Valganciclovir for the Prevention of Late Cytomegalovirus Infection After Allogenic Hematopoietic Stem Cell Transplantation.

Sponsor: City of Hope National Medical Center

Conditions Bone Marrow Stem Cell Transplant

Interventions Valganciclovir

Updated 6 times since 2017 Last updated: Dec 16, 2011 Started: Nov 30, 2001 Primary completion: Jul 31, 2007 Completion: Jul 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Bone Marrow Stem Cell Transplant, this trial is completed. The trial is conducted by City of Hope National Medical Center and has accumulated 6 data snapshots since 2001. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
May 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — May 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Nov 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

City of Hope National Medical Center
Fred Hutchinson Cancer Center
Mayo Clinic
Roche Pharma AG
University of Florida
University of Michigan

Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Rochester, United States